Conditions: Metastatic Breast Cancer Advanced Breast Cancer Metastatic Castration Resistant Prostate Cancer Metastatic Renal Cell Cancer Non-Small Cell Lung Cancer Thyroid Cancer Advanced/Metastatic Non-Small Cell Lung Cancer Advanced Gastric Cancer Gastrointestinal Stromal Tumor Hepatocellular Carcinoma Pancreatic Islet Cell Carcinoma Pancreatic Neuroendocrine Tumor
Keywords: Potentially other tumor types in the future
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 223
Healthy volunteers: no

Brief summary:
This is a study using sunitinib for patients ending treatment on a previous sunitinib malate protocol to continue to receive sunitinib. The patient must have been enrolled in one of the following studies: A6181030, A6181064, A6181078, A6181087, A6181094, A6181107, A6181108, A6181110, A6181111, A6181112, A6181113, A6181120, A6181126 and A6181170. Other Pfizer sponsored sunitinib studies may be included in the future.

Detailed description:

Arms:
arm 1: Sunitinib will be administered in a continuous daily dose (oral, once per day). Starting dose will be 37.5 mg daily unless the patient was on a different dose (25 mg or 50 mg daily) on the previous trial. In that case, they will begin treatment on this study at the same dose used at the end of the previous study.

The protocol now allows for patients on dosing regimens other than only continuous dosing (e.g. 4/2, etc.) to be enrolled if eligible.

Interventions: intervention 1: sunitinib
Intervention descriptions: intervention 1: sunitinib

Protocol document: